A

Adjuvants
- aluminum-based, 139
- CpG ODNs, see CpG oligonucleotides
- definition, 139
- double stranded RNA, 222
- Freund’s complete adjuvant, 271, 273, 371
- guidelines, 374
- mechanisms, 139
- see also pathogen-associated molecular patterns
- see also stress proteins

Allergy, see also type I allergy
- DNA vaccine, see also replicase-based DNA vaccine
- advantages, 253
- see also codon usage
- humoral response, 263, 264
  - see also rat basophil leukemia cell (RBL) release assay
  - antibody subclass distribution using ELISA, 265
- immunization/sensitization of mice, 263
- intradermal immunization, 263
- materials, 254, 255
- optimization strategies, 253
- overview, 253, 254
- pCI mammalian expression vector, 254
- plasmid purification, 260–262
- vector construction
  - Bet v 1a Fragments, 259
  - CpG-enriched vector, 255
- recoding of allergens, 257, 258
- ubiquitinated Bet v 1a, 260
- conventional immunotherapy (SIT), 253–254

Antibody
- assays
  - Western blot, 6
  - ELISA, 50, 62, 66, 79
- vaccine, 4

Antigen-presenting cells, 199, 200, 222
- see also dendritic cells
- antigen processing, 44, 204–205
- bone marrow chimeric mice, 281–282
- DNA vaccine, antigen presentation, 8, 44, 140, 142, 199, 203, 281
- APCs, see antigen-presenting cells

Autoimmune disease
- antigen recognition, 269
- Active Heymann Nephritis, 270

autoimmune encephalomyelitis (EAE), 270
- diabetes, 271

DNA vaccine
- auto-antibody isotype determination, 275–276
- autoreactive T cell isolation and establishment, 273–275
- cloning V(D)J joints, 273–274
- cloning expression plasmid, 274
- cytokine assay, 275
- detection of anti-TCR antibodies, 275
- materials, 271–273
- overview, 269–271
- pcDNA3, 272
- pCMV5, 272
- pTarget T, 272
- phCMV, 272
- vaccination, 275
Index

human membranous nephritis, 270
multiple sclerosis (MS), 269
rheumatoid arthritis (RA), 270
T-cell receptor, 270

Autoimmune responses
messenger RNA vaccination, 23
CpG ODN, 149
safety issues of DNA vaccines, 369, 371

Bacterial DNA, see plasmid vectors
BHV-1, see Bovine herpesvirus-1
Bioinjector, see needle-free delivery

Bone marrow chimeric mice
advantages, 282
cytotoxic T-lymphocytes, peptide epitope-specific activation studies
chromium-51 release assay, 285, 289, 290
materials, 281
rationale, 281, 282
splenocyte restimulation, 285, 288, 289, 291
generation
antibody production for T-Lymphocyte depletion, 285, 286
infection prophylaxis, 88, 295
isolation and injection of bone marrow cells, 284, 287
materials, 283–285
T-lymphocyte depletion, 284, 286, 287
plasmid DNA vaccine, 284, 288

Bovine herpes virus, 1, 75

C
Cardiotoxin, 272, 275
Cationic lipid, 127, 363
Cationic peptides
advantages, 159, 166–167
complex formation, 160, 164
quantification, 164–165
immunization, 164
materials, 162–163
overview, 159–160
plasmid preparation, 162, 163
pTKTHBV2, 162
specific CD8+T-cell frequencies, 164–165, 167
natural sources, 161

CBER, see Center for Biologics Evaluation and Research
Cell bank, 299–300, 368
Center for Biologics Evaluation and Research, 366
Chimpanzee, 147
Chromium-51 cytotoxic T lymphocyte response assay, see bone marrow chimeric mice
Clinical trials, 365
cGMP guidelines, 366
Codon usage, 203, 253, 257
CpG motifs, see also immunostimulatory sequences and CpG ODN
CpG ODN, see CpG oligonucleotides
CpG oligonucleotides (CpG ODN)
adjuvant properties, 140, 144
delivery, 146
DNA vaccine
animal studies, 147
human trials, 149, 150
immunocompromised hosts, 147
overview, 146
immune response
antigen-presenting cells, 140
B-cell stimulation, 140
cytokine secretion, 144
mice studies, 144–145
modification, 144, 146, 258
overview, 57
safety, 149–150
synthetic ODNs, 57
Dendrimer-like DNA, see dendrimers

Dendritic cells (DCs)
DNA vaccine, see also specific vaccines
vector construct, see also specific vaccines
pcDNA3, 5, 6
pVAX1, 13, 15–16

modifying APCs
codon optimization, 203
employment of cytokines and costimulatory, 206–207
see also electroporation, 202–203
intradermal delivery, 201
intranodal delivery, 201
intracellular spreading, 202
intracellular targeting, 203–204
ligands specific for APCs, 201

MHC-I/peptide expression, 204–205
prolonging DC survival, 206

TLRs, see toll-like receptors

DNA vaccine design, see also specific vaccines

Dendrimers
conjugation, 117, 118
dendrimer-like DNA activation, 117
dendrimer-like DNA sequence design, 118–119
delivery, 123
materials, 117

overview, 115–116
peptide selection, 116
purification, 118
sequence characterization, 120
sequence evaluation, 119–120
solid phase conjugation, 121–123
solution phase conjugation, 120–121

DCs, see also dendritic cells

Th1/Th2 cytokines
assay, 272, 275
definition, 270

intracellular spreading, 202
intracellular targeting, 203–204

iligands specific for APCs, 201

MHC-I/peptide expression, 204–205
prolonging DC survival, 206

intradermal delivery, 201
intranodal delivery, 201
intracellular spreading, 202
intracellular targeting, 203–204

ligands specific for APCs, 201

MHC-I/peptide expression, 204–205
prolonging DC survival, 206

TLRs, see toll-like receptors

DNA vaccine design, see also specific vaccines

ELISPOT, see also Enzyme-linked immunospot assay

Electroporation
delivery methods
intradermal injection, 78, 86, 201
intramuscular injection, 78, 87

immune responses
antibody response, 78, 79
interferon-γ ELISPOT, 81, 82
materials, 75–77
plasmid construction, 77
T-cell immunity, 80, 81
parameters, 74
single-needle, 75
Endocytic pathway
organelles, 127, 128
Endotoxins
acceptable levels, 313, 359
limulus amebocyte lysate (LAL), 62, 66–67, 313
cytotoxic effects, 342
overview, 260, 313
removal from plasmids, 260–262, 266, 353
transfection efficiency, 348, 349
Enzyme-linked immunosorbent assay (ELISA)
autoantibodies
materials, 272
methods, 276
cytokine measurement
materials, 61–62
preparation of mouse splenocytes, 60
ELISA reader, 95
humoral immunity, see serum antibody
immunoglobulin measurement, 61–62, 264
protein expression, 77
serum antibody detection
analysis, 50, 79, 80, 95, 102, 214, 265, 266
materials, 50, 76, 95, 210, 256
T-cell response, 184–185, 210
Enzyme-linked immunospot assay (ELISPOT)
B-cell responses
materials, 95
overview, 103
ELISPOT reader, 178, 189, 228, 249
T-cell responses
porcine
materials, 76, 96
isolation of PBMCS from porcine, 81
IFN-γ, 81
monkey
IFN-γ, 178, 187
materials, 178
preparation of macaque
PBMC, 188
mouse
IFN-γ, 215, 227, 245, 249
materials, 210, 224
IFN-γ, 215, 227, 245, 249
overview, 80, 103, 187, 215
Epitope
CD8+T-cell response, 167, 285
immune response, 8
DNA vaccine complex, 159, 162
European Union (EU), 365
guidelines for DNA vaccines, 374
Experimental autoimmune encephalitis (EAE), see autoimmune disease
F
FDA, see Food and Drug Administration
Fed-batch reactor, 295, 296
Fermentation
biomass processing, 319–325, 341, 342, 347
cultivation conditions, 301, 302, 341, 346
dissolved oxygen, 302
sample analysis, 304, 305
schematic, 302
Food and Drug Administration (FDA)
ALUM, 139
antibiotics, 12
CEBR, 366
clinical trials, 365
guidelines for DNA vaccines, 342–343, 373, 374
Qiagen procedure, 349
messenger RNA, 23
plasmid DNA vaccines, 374
Equine West Nile DNA vaccine, 295

G
Gene
cloning
restriction sites, 5–6
promoter, 5
protein expression, 6–7
reporter gene, 75
transcription, 7, 97
vaccine, 4
Gene gun, see needle-free delivery
Granulocyte macrophage-colony stimulating factor (GM-CSF), 8, 201, 241
DC culture, 34
immunostimulatory activities, 8, 35, 36, 201, 241–242

H
HBV, see Hepatitis B virus
Heat shock proteins, see stress proteins
Hepatitis B virus (HBV)
cationic peptides, 161, 162
CpG ODN, 144, 145
HBV vaccine, 86, 147
Hepatitis-B surface antigen express plasmid, 45–47, 147–148, 162
Hepatitis D virus, 160
HDV, see Hepatitis D virus
Herpes simplex virus (HSV)
VP22 or tegument protein, 8, 202
Human immunodeficiency virus (HIV)
animal models, 177, 184–185
small animals, 177, 184–185
macaques, 177, 185–186
CpG motifs, 141, 145–147
DNA vaccine
cellular immune response assay
ELISPOT, 178, 187–189
intracellular cytokine staining (ICS), 189–191
lymphoproliferation, 179, 192
humoral immune response, 179, 193
materials, 175–179
overview, 172
see also prime-boost vaccines
plasmid construction
3' HIV-1 sequence modification, 183
5' HIV-1 sequence modification, 181
B Clade HIV-1 genome modification, 180
materials, 175–177
splicing strategy, 181–183
pHIS-HIV-B, 180
recombinant Fowlpox virus vaccine, 183–185
TAT peptide sequence, 116, 159–162
T-cell response, 171
Human papillomavirus (HPV)
HPV-16 DNA vaccine
CD8+ T cell responses
activation, 214
CD11c+ preparation, 209, 213
cytokine staining, 210–212, 215–216
ELISPOT assay, 211, 215
MHC tetramer, 211, 216–217
delivery, 211, see also gene gun
epitope, 205
humoral responses
ELISA assay, 211, 214
immune response assay, 214–215
in vivo antibody depletion, 213
in vivo protection, 209, 212
in vivo treatment, 209, 212
materials, 208–210
murine tumor model, 208
mouse TC-1 cells
production and maintenance, 208–209
oncoproteins,
  E2, 6
  E6, 5, 208
  E7, 5, 208

I
Immune responses
antigen-presenting cell role, 200
  cell-mediated
    see Enzyme-linked immunospot assay and specific vaccines
    overview, 4
    specific CD8+ T-cell frequencies, 49
humoral immunity assays, 263–265
  see Enzyme-linked immunosorbent assay and specific vaccines
  serum antibody, 50
  Western blot, 178, 193
lymphoproliferation, 179, 192

Immunostimulatory DNA sequence (ISS), 57
Industrial quantity production of plasmids
bioreactors, 295, 296
cell bank preparations, 299, 300
fermentation, see fermentation
host selection, 345, 346
lysis of bacteria, 347
materials, 296, 297, 344
medium preparation, 297–299
overview, 295, 296
quality assurance and quality control, 342, 343, 347, 348
sample and analytical methods, 204, 205
ISS, see also Immunostimulatory DNA sequence

L–M
LAL assay, see also limulus amebocyte lysate assay
Limulus amebocyte lysate assay, see Endotoxin
Major histocompatibility complex (MHC)
  antigen presentation, 203, 204
  expression, 204, 205
  invariant chain (Ii), 204
tetramer staining, 211, 216
Malaria, 147, 239, 240
Medicines Control Agency (United Kingdom), 343
Messenger ribonucleic acid (RNA)
  injection, 35, 36
  plasmid template linearization, 28, 29
  production, 26
  quantification, 27, 28
  production transcription, 29, 30
  purification, 30–33
  safety issues, 23, 24
  transfection, 34, 35
  vaccine dendritic cell-based, 33, 34
  vector construct
    T7TS, 25
Microspheres
materials, 108
overview, 107, 108
production
  emulsion, 108–110
  surface modification, 110–112

N
Needle-free delivery
barriers, 92
Bioinjector, 86–88, 93, 98, 99
DNA vaccines, 84–86
gene gun, 93, 99, 100
vaccination, 208
Index

history, 84
intradermal, 86, 87
materials, 93–96
suppositories, 93, 100
Neonatal DNA vaccines
immune response
  antibody response, 247
  cytotoxic T lymphocyte assay, 245
  interferon-γ detection using ELISPOT, 245
immunization, 243
materials, 241
overview, 239–241
  production of neonates, 242, 243
NLS, see nuclear localization peptide
Nuclear localization peptide, 116

O–P
Oncoproteins, 5
Pathogen-associated molecular patterns (PAMPs), 140
Pattern recognition receptors (PRR), 140, see also toll-like receptors
Plasmids
  adverse immunopathology, 370
  antibiotic markers, 12, 316
  cloning, 272, 274, 275
  construction
    antigen insert, 15, 16
    clone verification, 16, 17
    gene insertion, 16
    modification, 180–184
    overview, 4–7
  production, 17, 18, 175, 176, 180
    verify clones, 16, 17
  industrial quantity production, see industrial quantity production of plasmids
  immunostimulatory properties, see immunostimulatory DNA sequences
  integration, 369, 370
pHIS-64, 180
promoter, 11
purification, see purification of plasmids
regulatory process
  developmental review, 367
  licensing, 365, 366
  safety, 365, 366, 369, 370–373
  replication, 11, 12
  stress protein incorporation, 43, 44, see also heat shock proteins
terminator, 11
vectors, see plasmid vectors
Plasmid vectors, see also specific vectors
  immunostimulatory sequences (ISS), 57–59
  immunological activities, 57–58
  in vitro assay of activities
    assessment of endotoxin, 62, 66–67
    cytokine secretion, 62, 65–66
    immunoglobulin determination, 62, 66
  isolation of splenocytes, 63, 60–61
  materials, 60–62
  overview, 59–60
  proliferation of splenocytes, 61
  thymidine incorporation, 64, 65
  overview, 12, 13, 56–59
toll-like receptors, 56
Polymerase chain reaction (PCR), 5, 6, 254
Prime-boost vaccines
  advantages, 172–175
  see Human immunodeficiency virus immune response
  cell surface marker staining, 190, 191
  cellular immune response using ELISPOT, 187–189
  humoral immunity, 193
interferon-γ staining, 191
intracellular cytokine staining, 189, 190
lymphoproliferation, 192
immunization, 184, 185
materials, 175–179
plasmid construction, 179, 180
splicing, 181–183
vaccine construction, 183

Purification of plasmids
anion exchange, 330–332, 344, 347
calcium silicate batch adsorption, 353, 354, 356, 357, 360
clarification, 352, 353, 355
CTAB precipitation, 353, 356, 359, 360
diafiltration/ultrafiltration, 326, 327
equipment, 317–319
hydrophobic interaction, 332, 333
impurities, 313–315, see also endotoxins
reverse-phase, 333, 336
size-exclusion, 332
ultrafiltration concentration, 354, 357, 358, 360

Q
Quality assurance and safety
cell bank/starting materials, 368, 369
clinical trials, 365
developmental review, 368
guidelines, 366, 367
integration, 5, 11, 19, 23, 365, 369, 372–373
non-clinical safety, 365
non-clinical safety testing, 372, 373
overview, 363, 364
postlicensing, 366
product license, 365, 366
quality, 364, 365, 367
regulatory process, 364
safety issues, 369–372

R
Rat basophil leukemia (RBL) release assay
materials, 255
RBL cell culturing, 264
β-Hexosaminidase release, 264
Replicase-based DNA vaccines
cellular response assays
cytokine fluorescent bead immunoassay, 231, 232
cytokine secretion by FACS, 228–231
ELISPOT, 227, 228
proliferation, 227
collection, 225
immunization/sensitization of mice, 226, 227
materials, 223–225
overview, 221, 222
plasmid construct
pSinRep5, 223
Rheumatoid arthritis (RA), 270

S
Self-replicating DNA vaccines, see replicase-based DNA vaccines
Self-tolerance, 269
Serum antibody, see antibody
Stress proteins
expression, 45, 46, 204
immunization with, 49, 50, 202
purification, 48, 49
transfection, 47
vaccine
immune response, 49, 50
overview, 44
protein expression, 48
pTKTHBV2, 45
transfection, 47
vectors, 45–47
Western blot analyses, 48, 49
Subcellular trafficking compartments
endosomes, 131–132
Index

golgi network, 132–133
immunofluorescence labeling materials, 129–130
late endosomes, 132
lysosomes, 133
overview, 127–129
sorting endosomes, 131–132
recycling compartment, 132
trans-Golgi network, 133, 134

Supercoiled DNA production
host/clone selection, 317
impurities
see endotoxins
genomic DNA, 315
overview, 311, 312
proteins, 314
ribonucleic acid, 315
topoisomers of DNA, 316
plasmid
construction, 316
propagation, 315, 316
production
biomass generation and harvesting, 317, 318
buffers, 321, 322
growth, 318, 319
lysis, 322, 323
lysis clarification, 323–325
neutralization, 323
processing biomass, 319, 320
purification, see also plasmids, purification
suspension, 322

Suppositories, see needle-free delivery

Synthetic oligonucleotides, see CpG oligonucleotides

T
TLRs, see toll-like receptor
T-lymphocytes
anti-TCR antibodies, 272, 275
auto-reactive T-cells, 271, 273
depletion of T-lymphocytes, 286
regulatory T-cells, 270–271
targeting pathogenic T-cells, 270
T-cell receptor (TCR), 269, 270
primers for cloning TCR Vβ8.2, 277
rearrangements, 269
restricted usage of TCR in autoimmune disease, 270
TCR genes, 276
TCR variable regions, 270–271
Toll-like receptors (TLRs)
CpG recognition, 281, 141–143
expression, 56
immune response, 140
signaling pathway, 56
Trastuzumab (Herceptin), 4
Tumor
antigen, 41, 116, 202
DNA vaccine, 205, 206, see also HPV
immune response
antigen ELISA, 214
CD8+ staining, 216
CD8+ T-cell response, 213, 214
flow cytometry analysis, 215
intracellular cytokine staining, 215
major histocompatibility complex staining, 216
T-cell ELISPOT assay, 215
production and maintenance, 208, 209, 212
see also mRNA vaccines
oncoproteins, 5
tumor-associated protein, 5
Type I allergy, 253–254

U–W
Ubiquitin, 203, 204, 260
Vectors, see plasmid vectors and see also specific vectors
Veterinary DNA vaccine
barriers, 91, 92
cellular immune response, 102, 103
cell infiltration, 102

delivery
  gene gun, 99, 100
  needle-free jet injection, 98, 99
  suppositories, 100

humoral response, 102, 103

materials, 94–96

pcDNA3, 97

pcDNA4, 97

plasmid construction, 96, 97

protective antigens assay, 101, 102

protein production
  green fluorescent protein, 101
  luciferase, 101

World Health Organization (WHO)
  Guidelines for DNA vaccines, 373